How do autoantibodies against the Jo-1 antigen affect the clinical course of polymyositis?

Updated: Jan 05, 2021
  • Author: Mythili Seetharaman, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print

The presence of autoantibodies against the Jo-1 antigen has been reported in up to 23% of polymyositis patients by immunodiffusion. Anti–Jo-1 antibodies are almost completely specific for myositis and are more common in polymyositis than in dermatomyositis; they are rare in children. The presence of anti-Jo-1 antibodies defines a distinct group of polymyositis patients with interstitial lung disease, arthritis, and fevers. The anti–Jo-1 response appears to be self-antigen driven, having a broad spectrotype over time and undergoing isotype switching. Anti–Jo-1 antibodies also inhibit the function of histidyl-tRNA synthetase in humans more than they do in other species.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!